Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114070112 | 11407011 | 2 | F | 201506 | 20150910 | 20150821 | 20160826 | PER | US-NOVOPROD-453496 | NOVO NORDISK | 73.00 | YR | E | M | Y | 100.68000 | KG | 20160826 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114070112 | 11407011 | 1 | PS | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 1.8 MG, QD | Y | UNKNOWN | 22341 | 1.8 | MG | SOLUTION FOR INJECTION | QD | ||||
| 114070112 | 11407011 | 2 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | UNK | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 114070112 | 11407011 | 1 | Type 2 diabetes mellitus |
| 114070112 | 11407011 | 2 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 114070112 | 11407011 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 114070112 | 11407011 | Pancreatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 114070112 | 11407011 | 1 | 201303 | 201506 | 0 |